Inozyme Pharma

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Inozyme Pharma sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 3 currently recruiting 5 completed early-phase tilt top decile by trial count

Inozyme Pharma: 9 sponsored US clinical trials, 3 recruiting.

Inozyme Pharma sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, with 5 trials.

Top-decile sponsor footprint

Inozyme Pharma ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING

PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency

NCT06302439
RECRUITING Phase 2

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

NCT06462547
RECRUITING Phase 1

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

NCT05734196
ACTIVE NOT RECRUITING Phase 3

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

NCT06046820
COMPLETED Phase 1

The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis

NCT06283589
COMPLETED

Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency

NCT05050669
COMPLETED Phase 1

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

NCT05030831
COMPLETED Phase 1

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

NCT04686175
COMPLETED

Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency

NCT04372446

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1
Phase 3 1

Therapeutic Areas

Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency 5
Generalized Arterial Calcification of Infancy 3
Autosomal Recessive Hypophosphatemic Rickets 3
Autosomal Recessive Hypophosphatemic Rickets Type 2 2
Pseudoxanthoma Elasticum 2
ATP-Binding Cassette Subfamily C Member 6 Deficiency 2
Generalized Arterial Calcification in Infancy 1
Arterial Calcification 1
Gene Mutations 1

What is open in the Inozyme Pharma pipeline

3 recruiting of 9 indexed (33% open); 5 completed (56%).

Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency (5 trials), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Inozyme Pharma: open-pipeline peers nationwide

Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Inozyme Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40%50% Total trials Recruiting share Inozyme Pharma4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyAaron CookAbivax S.A.Actuated MedicalAdagio Medical
Inozyme Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Inozyme Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Inozyme Pharma page

9 registered trials is a research-attention snapshot, not an endorsement of Inozyme Pharma or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Inozyme Pharma pipeline card: 9 registered trials from official public datasets.Report a data error.